Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats.
Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP(®) 8 (MERIAL) and BOVILIS(®) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines.
ANSES, UMR Virology 1161, Laboratoire de Sante Animale, Maisons-Alfort, France. emmanuel.breard@anses.fr
E
E
Bréard
G
G
Belbis
C
C
Hamers
V
V
Moulin
T
T
Lilin
F
F
Moreau
Y
Y
Millemann
C
C
Montange
C
C
Sailleau
B
B
Durand
A
A
Desprat
C
C
Viarouge
B
B
Hoffmann
H
H
de Smit
S
S
Goutebroze
P
P
Hudelet
S
S
Zientara
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001819:Bluetongue / Q000276:immunology / Q000517:prevention & control*; D001820:Bluetongue virus / Q000276:immunology*; D005062:European Union; D005260:Female; D015511:Goat Diseases / Q000276:immunology / Q000517:prevention & control*; D006041:Goats; D014611:Vaccination / Q000379:methods; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014766:Viremia / Q000517:prevention & control
D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines